ASCENT — Global Competitive Landscape Report 2026 | EHA 2026

ASCENT is included as an EHA 2026 clinical study keyword linked to Multiple Myeloma Combination Therapy in Aggressive Smoldering Multiple Myeloma.

This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.

Executive Summary

ASCENT (NCT03289299) — Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant — is an International Myeloma Foundation (IMF) sponsored Phase 2 study that tests a curative-intent quadruplet carfilzomib + lenalidomide + daratumumab + dexamethasone (KRd + Dara) in high-risk smoldering multiple myeloma (HR-SMM) patients. The trial uses a three-phase design — 6-cycle induction + 6-cycle consolidation + 12-cycle maintenance across 24 total 28-day cycles. Amgen, Janssen Scientific Affairs, and Celgene collaborate as pharmaceutical partners. For EHA 2026, ASCENT is flagged as a keyword-expansion trial serving the SEO cluster around HR-SMM curative-intent therapy, KRd+Dara quadruplet regimens, and disease-precursor multiple myeloma intervention.

Why this trial matters

ASCENT sits at the strategic crossroads of high-risk smoldering myeloma treatment philosophy. HR-SMM patients face ~50% risk of progression to active myeloma within 2 years — a population where AQUILA (daratumumab SC monotherapy) shifted the field toward early intervention and where ImmunoPRISM (teclistamab BCMA bispecific) + LINKER-SMM2 (linvoseltamab BCMA bispecific) + ERASMM (elranatamab) tests aggressive immunotherapy layering. ASCENT takes a fundamentally different approach: quadruplet KRd+Dara curative-intent therapy modeled on newly diagnosed myeloma induction protocols. The trial asks whether intensive curative-intent quadruplet regimens can eliminate the aberrant plasma-cell clone before symptomatic myeloma emerges — potentially delivering true disease modification or functional cure in HR-SMM.

Pipeline framing

Notably, the Patsnap Eureka pharma-intelligence stack identifies 121 HR-SMM Phase 2/3 trials across five treatment philosophies. Curative-intent quadruplets: ASCENT (KRd+Dara IMF), DARA RVD PRISM (Dara+VRd Dana-Farber Phase 2). CD38 mAb monotherapy: AQUILA (Dara SC vs monitoring Janssen Phase 3, 2024 positive). CD38 mAb + IMiD triplets: DETER-SMM (Dara+Rd SWOG/ECOG Phase 3), HO147SMM (KRd vs Rd Dutch Phase 2), Carfilzomib + KRd Spanish Phase 2. Anti-CD38 + IMiD immunotherapy: MODIFY (Isa + Iberdomide Phase 2), Iberdomide ± Dex Phase 2. BCMA cell therapy: ImmunoPRISM (Teclistamab Dana-Farber Phase 2), LINKER-SMM2 (Linvoseltamab Regeneron Phase 3), ERASMM (Elranatamab Pfizer Phase 2), CAR-HiRiSMM (Ciltacabtagene J&J Phase 2). ASCENT represents the KRd+Dara curative-intent quadruplet approach against increasingly aggressive BCMA immunotherapy alternatives.

---

Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.

Arena Overview

ASCENT snapshot — NCT03289299 sponsored by the International Myeloma Foundation (IMF) with Amgen (carfilzomib), Janssen Scientific Affairs (daratumumab), and Celgene (lenalidomide + dexamethasone) as pharmaceutical collaborators. Enrollment: adults with high-risk smoldering multiple myeloma defined by 20-2-20 criteria or equivalent risk stratification. Design: single-arm three-phase quadruplet — Induction (6 × 28-day cycles KRd+Dara) → Consolidation (6 × 28-day cycles KRd+Dara) → Maintenance (12 × 28-day cycles). Total 24 cycles of KRd+Dara-based therapy. Primary endpoints: MRD-negative complete response rate + rate of biochemical progression-free survival + safety composite. Trial status: active, not recruiting — final follow-up data collection ongoing.

KRd+Dara quadruplet pipeline snapshot

ASCENT’s KRd+Dara quadruplet regimen combines three approved myeloma agents each with distinct mechanisms. Kyprolis (carfilzomib, Amgen, FDA 2012-07 R/R MM + 2015-07 R/R combinations + 2016-01 1L R+d combinations) — irreversible second-generation proteasome inhibitor. Revlimid (lenalidomide, BMS/Celgene, FDA 2005-12 MDS + 2006-06 R/R MM + 2015-02 1L NDMM) — immunomodulator (IMiD). Darzalex (daratumumab, Janssen originator Genmab, FDA 2015-11 R/R MM + 2019-06 1L TI NDMM via MAIA) — first CD38 mAb. Dexamethasone — standard corticosteroid. Combined, the KRd+Dara quadruplet delivers deep MRD-negative CR rates in NDMM (~80%+ in fit patients) — ASCENT tests whether this depth achievable in HR-SMM enables disease modification.

HR-SMM curative-intent field context

The HR-SMM curative-intent landscape competes across five treatment philosophies. Curative quadruplet regimens: ASCENT (KRd+Dara IMF Phase 2), DARA RVD PRISM (Dara+VRd Dana-Farber Phase 2 quadruplet). CD38 mAb monotherapy early intervention: AQUILA (Dara SC vs monitoring Janssen Phase 3 2024 positive). CD38 mAb + IMiD triplets: DETER-SMM (Dara+Rd Phase 3), MODIFY (Isa + Iberdomide Phase 2). BCMA bispecific: ImmunoPRISM (Tec Dana-Farber Phase 2), LINKER-SMM2 (Linvoseltamab Regeneron Phase 3), ERASMM (Elranatamab Pfizer Phase 2). BCMA CAR-T + BsAb: CAR-HiRiSMM (Ciltacabtagene J&J Phase 2), BCMA/CD3 BsAb Phase 1 China. ASCENT curative quadruplet delivers proven MRD depth but adds carfilzomib + intensive multi-cycle exposure — a tolerability trade-off distinct from AQUILA/BCMA immunotherapy strategies.

Player Summary Table

Player	Region	Tier	Primary Route	Key Evidence
International Myeloma Foundation (ASCENT)	US	T1 (Curative-intent quadruplet HR-SMM)	KRd+Dara 24-cycle induction+consolidation+maintenance	ASCENT NCT03289299 IMF Phase 2 US Amgen+Janssen+Celgene collaborators
Dana-Farber (DARA RVD PRISM)	US	T1 (Quadruplet HR-SMM PRISM platform)	Dara + VRd 4-drug induction	DARA RVD PRISM Phase 2; Dana-Farber PRISM cooperative-group platform
Janssen (AQUILA)	US/BE	T1 (Dara SC monotherapy standard-of-care)	Daratumumab SC vs active monitoring	AQUILA Phase 3 (2024 positive readout PFS + biochemical PFS in HR-SMM)
SWOG + ECOG (DETER-SMM)	US	T2 (CD38 mAb triplet)	Daratumumab + Rd vs Rd	DETER-SMM Phase 3 SWOG/ECOG cooperative-group HR-SMM
Regeneron + Dana-Farber + Pfizer (BCMA HR-SMM programs)	US	T1 (BCMA immunotherapy HR-SMM)	Linvoseltamab + Teclistamab + Elranatamab	LINKER-SMM2 Phase 3 + ImmunoPRISM Phase 2 + ERASMM Phase 2
Legend Biotech + J&J (CAR-HiRiSMM)	CN/US	T2 (BCMA CAR-T HR-SMM)	Ciltacabtagene autoleucel BCMA CAR-T	CAR-HiRiSMM Phase 2 in HR-SMM
Amgen (Kyprolis carfilzomib supplier)	US	T1 (2nd-gen PI backbone in ASCENT)	Carfilzomib 2nd-generation proteasome inhibitor	Kyprolis (2012-07 R/R MM + 2015-07 combinations + 2016-01 1L R+d)

Adjacent HR-SMM Emerging + Supplier Players

Player	Region	Tier	Primary Route	Key Evidence
BMS + Celgene (Revlimid + Iberdomide)	US	T1 (IMiD backbone in ASCENT + next-gen CELMoDs)	Lenalidomide + Iberdomide next-gen	Revlimid (2005-12) + Iberdomide Phase 2 HR-SMM MODIFY
Sanofi (Sarclisa MODIFY)	FR	T2 (Anti-CD38 mAb alternative)	Isatuximab + Iberdomide	Sarclisa (2020-03) + MODIFY Phase 2 HR-SMM combination
PharmaEssentia (Ropeg-INF-α)	TW	T3 (Interferon-based HR-SMM)	Ropeginterferon alfa-2b	Ropeg-INF-α Phase 4 HR-SMM investigator-sponsored trial
Dutch HOVON (HO147SMM)	NL	T2 (European KRd triplet)	Carfilzomib + Rd vs Rd	HO147SMM Phase 2 European HR-SMM triplet trial
Spanish + French cooperative groups	ES/FR	T3 (Regional HR-SMM protocols)	Carfilzomib + KRd variants + Isa + Iberdomide combinations	Multiple regional Phase 2 trials with heterogeneous designs
Chinese cooperative groups (BCMA/CD3 BsAb)	CN	T3 (Regional BCMA immunotherapy)	BCMA-CD3 bispecific antibody HR-SMM	BCMA/CD3 BsAb early Phase 1 HR-SMM

---

Route Differentiation Analysis

In particular, five therapeutic routes define how sponsors compete around ASCENT in the HR-SMM curative-intent landscape.

Route × Player Matrix

Player	Curative Quadruplet KRd+Dara / Dara+VRd	Dara SC Monotherapy	CD38 mAb + IMiD Triplet	BCMA Bispecific Monotherapy	BCMA CAR-T Curative-Intent
International Myeloma Foundation (ASCENT)	Strong — ASCENT KRd+Dara 24-cycle curative-intent quadruplet	Absent	Absent	Absent	Absent
Dana-Farber (DARA RVD PRISM + ImmunoPRISM + CAR-PRISM)	Strong — DARA RVD PRISM Dara+VRd quadruplet	Absent	Absent	Strong — ImmunoPRISM Teclistamab Phase 2	Strong — CAR-PRISM Cilta-cel Phase 2
Janssen (AQUILA + Dara franchise)	Backbone — Dara supplier in ASCENT	Strong — AQUILA Dara SC vs monitoring Phase 3 2024 positive	Backbone — Dara supplier in DETER-SMM	Absent	Absent
SWOG + ECOG (DETER-SMM)	Absent	Absent	Strong — DETER-SMM Dara+Rd Phase 3	Absent	Absent
Regeneron + Pfizer + Dana-Farber (BCMA bispecifics HR-SMM)	Absent	Absent	Absent	Strong — LINKER-SMM2 + ERASMM + ImmunoPRISM BCMA bispecifics	Absent
Legend Biotech + J&J (CAR-HiRiSMM)	Absent	Absent	Absent	Absent	Strong — CAR-HiRiSMM Cilta-cel HR-SMM Phase 2
Amgen + BMS/Celgene (backbone suppliers)	Backbone — Kyprolis + Revlimid + Dex in ASCENT	Absent	Backbone — Revlimid in DETER-SMM	Absent	Absent

Route Concentration Observations

• Curative quadruplet KRd+Dara — Additionally, IMF’s ASCENT and Dana-Farber’s DARA RVD PRISM share the curative-intent quadruplet approach. As a result, both trials generate parallel evidence bases for HR-SMM quadruplet MRD depth + biochemical PFS — a treatment philosophy distinct from AQUILA/BCMA alternatives.
• Dara SC monotherapy standard-of-care — Meanwhile, AQUILA Phase 3 2024 positive readout established Dara SC vs active monitoring as HR-SMM early-intervention standard. In contrast, ASCENT quadruplet must demonstrate meaningful depth-of-response benefit over AQUILA monotherapy to justify quadruplet tolerability burden.
• CD38 mAb + IMiD triplet — In contrast, DETER-SMM (Dara + Rd) provides Phase 3 randomized triplet evidence between AQUILA monotherapy and ASCENT quadruplet complexity. As a result, DETER-SMM readout will inform whether triplet delivers most of quadruplet benefit at reduced complexity.
• BCMA bispecific monotherapy HR-SMM — Similarly, LINKER-SMM2 (Linvoseltamab Phase 3) + ImmunoPRISM (Teclistamab Phase 2) + ERASMM (Elranatamab Phase 2) test aggressive BCMA immunotherapy in HR-SMM. In contrast, BCMA bispecifics deliver deep responses without long-term chemotherapy exposure but face CRS/infection concerns.
• BCMA CAR-T curative-intent — Furthermore, CAR-HiRiSMM (Ciltacabtagene autoleucel) + CAR-PRISM test BCMA CAR-T as one-time curative-intent alternative to ASCENT’s 24-cycle quadruplet. As a result, BCMA CAR-T convenience + potential functional cure competes with ASCENT quadruplet MRD depth + established multi-drug efficacy.

---

Top Player Deep Dives

1. International Myeloma Foundation — ASCENT (Tier 1 — Curative-intent HR-SMM quadruplet)

Primary route: KRd + Dara quadruplet (carfilzomib + lenalidomide + daratumumab + dexamethasone) delivered in 24 total 28-day cycles across three sequential treatment phases (6-cycle induction + 6-cycle consolidation + 12-cycle maintenance) in high-risk smoldering multiple myeloma patients — a curative-intent approach modeled on NDMM induction protocols.

Key infrastructure: International Myeloma Foundation (IMF) sponsors ASCENT — the leading global myeloma patient advocacy + research foundation. Pharmaceutical collaborators: Amgen (carfilzomib Kyprolis), Janssen Scientific Affairs (daratumumab Darzalex), Celgene (lenalidomide Revlimid + dexamethasone). Single-country US enrollment.

Pivotal design

ASCENT (NCT03289299) — Phase 2 single-arm; active, not recruiting; US-only enrollment. Population: adults with high-risk smoldering multiple myeloma defined by 20-2-20 criteria (M-protein ≥ 20 g/L, involved-uninvolved FLC ratio ≥ 20, or bone marrow plasma cell ≥ 20%) or equivalent risk stratification. Design: Induction phase (6 × 28-day cycles KRd + Dara) → Consolidation phase (6 × 28-day cycles KRd + Dara) → Maintenance phase (12 × 28-day cycles). Primary endpoints: MRD-negative complete response rate at end of induction + end of consolidation; rate of biochemical progression-free survival. Key secondaries: ORR, VGPR/CR rate, sustained MRD-negative response, safety composite, patient-reported outcomes.

Differentiation: Notably, ASCENT is the only IMF-sponsored Phase 2 quadruplet KRd + Dara curative-intent trial in HR-SMM. As a result, positive ASCENT MRD-negative CR rate + sustained biochemical PFS could establish HR-SMM curative-intent framework — potentially shifting field philosophy from “monitor + intervene late” toward “treat with intent to cure” in aggressive smoldering disease.

Trajectory: Moreover, IMF sponsors ASCENT alongside broader HR-SMM research portfolio. Combined with Dana-Farber DARA RVD PRISM parallel quadruplet, ASCENT delivers cross-institution evidence base for HR-SMM curative-intent quadruplet regimens.

Key risk: However, quadruplet tolerability burden in HR-SMM (a still-asymptomatic disease state) faces significant risk-benefit scrutiny. If ASCENT quadruplet toxicity exceeds AQUILA Dara SC monotherapy without commensurate MRD or PFS benefit, the curative-intent thesis compresses to specific ultra-high-risk subgroups.

ASCENT Trial Design Snapshot

Element	Detail
Trial registration	NCT03289299 (ASCENT: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant)
Sponsor	International Myeloma Foundation
Collaborators	Amgen (Kyprolis carfilzomib) + Janssen Scientific Affairs (Darzalex daratumumab) + Celgene (Revlimid lenalidomide + dex)
Country	United States (single-country enrollment)
Population	High-risk smoldering multiple myeloma (20-2-20 criteria or equivalent risk stratification)
Design	Phase 2 single-arm; 3-phase: Induction (6 cycles) → Consolidation (6 cycles) → Maintenance (12 cycles); 24 total 28-day cycles KRd + Dara
Primary endpoint	MRD-neg CR rate + biochemical PFS
EHA 2026 context	Keyword-expansion trial for HR-SMM curative-intent quadruplet therapy

2. Dana-Farber — DARA RVD PRISM + ImmunoPRISM + CAR-PRISM (Tier 1 — HR-SMM cooperative platform)

Primary route: Multi-arm PRISM (Precision Redefined for Improved Screening for Myeloma) cooperative-group platform running parallel HR-SMM trials across three treatment philosophies — DARA RVD PRISM quadruplet, ImmunoPRISM teclistamab, CAR-PRISM ciltacabtagene — enabling head-to-head-like evidence generation.

Key programs: DARA RVD PRISM (Dara + VRd quadruplet Phase 2 in HR-SMM) — parallel curative-intent quadruplet to IMF ASCENT with bortezomib instead of carfilzomib. ImmunoPRISM (Teclistamab Phase 2 in HR-SMM) — BCMA bispecific monotherapy. CAR-PRISM (Ciltacabtagene autoleucel Phase 2 in HR-SMM) — BCMA CAR-T curative-intent.

Differentiation: Notably, Dana-Farber’s PRISM platform provides multi-modality HR-SMM evidence within single institution — enabling comparison of quadruplet vs bispecific vs CAR-T approaches in similar patient populations. As a result, PRISM findings will guide field-wide HR-SMM treatment philosophy convergence.

Trajectory: Moreover, Dana-Farber PRISM platform is closely integrated with Genmab (daratumumab), Janssen (teclistamab), and Legend Biotech + J&J (ciltacabtagene). Combined evidence base could reshape HR-SMM guidelines within the 2027-2028 window.

Key risk: However, non-randomized cross-platform comparisons face confounding variables. If PRISM platform interpretation favors one modality without randomized comparison to alternatives, guideline updates may lag until formal Phase 3 head-to-head data.

3. Janssen — AQUILA + Dara Franchise (Tier 1 — CD38 mAb SC monotherapy standard)

Primary route: Daratumumab (Darzalex) subcutaneous monotherapy vs active monitoring in HR-SMM — the AQUILA Phase 3 2024 positive readout that established Dara SC as HR-SMM early-intervention standard. Also anchors Dara supply for every quadruplet including ASCENT.

Key products: Darzalex (daratumumab IV, Janssen originator Genmab, FDA 2015-11 R/R MM). Darzalex Faspro (daratumumab + hyaluronidase SC, FDA 2020-05 R/R MM + 2022 1L combinations). AQUILA Phase 3 (2024 positive) established Dara SC monotherapy in HR-SMM. Janssen also develops MAIA (Dara + Rd 1L TI NDMM) + CEPHEUS (Dara + VRd 1L TI) + Tecvayli/Talvey (BiTE) + Carvykti (CAR-T).

Differentiation: Specifically, AQUILA delivers Dara SC monotherapy simplicity + demonstrated biochemical PFS benefit vs monitoring. As a result, ASCENT quadruplet must exceed AQUILA benefit by margin justifying quadruplet complexity + tolerability burden.

Trajectory: Moreover, Janssen positions Dara as foundation across HR-SMM (AQUILA) + 1L TI NDMM (MAIA, CEPHEUS) + 1L transplant-eligible (PERSEUS) + R/R combinations. Combined multi-line CD38 franchise dominates myeloma commercial economics through 2028+.

Key risk: However, if ASCENT + DARA RVD PRISM quadruplets demonstrate meaningful benefit over AQUILA monotherapy, guideline updates may recommend quadruplet in select ultra-high-risk HR-SMM subsets — modestly compressing AQUILA monotherapy addressable market.

4. Amgen — Kyprolis + Second-Gen Proteasome Inhibitor (Tier 1 — Backbone PI in ASCENT)

Primary route: Carfilzomib (Kyprolis) as second-generation irreversible proteasome inhibitor combined with lenalidomide + daratumumab + dexamethasone in the KRd+Dara ASCENT quadruplet — Amgen’s participation as backbone PI supplier in HR-SMM curative-intent research.

Key product: Kyprolis (carfilzomib, Amgen + Onyx, FDA 2012-07 R/R MM + 2015-07 R/R MM combinations + 2016-01 1L R+d combinations + 2019-02 Kd 1L combinations). Second-generation PI with different tolerability profile vs bortezomib — cardiac + infusion reactions vs bortezomib peripheral neuropathy. Amgen also develops other myeloma programs including Blincyto adjacencies.

Differentiation: Notably, carfilzomib delivers deeper MRD-negative CR rates in NDMM than bortezomib in some triplet comparisons (FORTE, ENDURANCE). As a result, ASCENT KRd+Dara quadruplet potentially delivers deeper HR-SMM responses than DARA RVD PRISM VRd+Dara quadruplet — bortezomib vs carfilzomib backbone choice matters.

Trajectory: Moreover, Kyprolis franchise growth depends on continued 1L + 2L expansion + emerging HR-SMM opportunities. Combined with generic bortezomib erosion, carfilzomib maintains PI premium positioning through 2028+.

Key risk: However, carfilzomib cardiac + infusion reactions require careful patient selection in HR-SMM asymptomatic population. Older HR-SMM patients may not tolerate KRd+Dara quadruplet — limiting ASCENT approach to fit high-risk subset.

5. BCMA Bispecific + CAR-T Consortium (Tier 1 — Alternative HR-SMM immunotherapy)

Primary route: BCMA-CD3 bispecific antibodies + BCMA CAR-T therapies moving into HR-SMM curative-intent territory — Regeneron LINKER-SMM2, Dana-Farber ImmunoPRISM, Pfizer ERASMM, Janssen + Legend CAR-HiRiSMM — alternative to ASCENT quadruplet approach.

Key programs: LINKER-SMM2 (Linvoseltamab, Regeneron, Phase 3) — first Phase 3 BCMA bispecific HR-SMM. ImmunoPRISM (Teclistamab, Dana-Farber, Phase 2). ERASMM (Elranatamab, Pfizer, Phase 2). CAR-HiRiSMM (Ciltacabtagene autoleucel, Legend Biotech + J&J, Phase 2). Additional Chinese BCMA-CD3 BsAb Phase 1 trials.

Differentiation: Notably, BCMA immunotherapies deliver deep responses without long-term chemotherapy exposure — a fundamentally different tolerability profile from ASCENT 24-cycle KRd+Dara quadruplet. As a result, BCMA HR-SMM approaches compete with ASCENT on convenience + tolerability + potential single-modality efficacy.

Trajectory: Moreover, BCMA bispecifics + CAR-T franchises expand into HR-SMM as strategic frontier. Combined with 1L NDMM Phase 3 programs, BCMA multi-line franchise could shape HR-SMM philosophy through 2028+.

Key risk: However, CRS + ICANS + infection risks in BCMA immunotherapy limit HR-SMM asymptomatic-patient risk-benefit. If BCMA HR-SMM shows unacceptable AE profile in still-asymptomatic patients, ASCENT quadruplet retains preferred positioning despite complexity.

6. Genmab + BMS + Celgene — CD38 mAb Discovery + IMiD Backbone (Tier 1 — Supplier network)

Primary route: Underlying discovery + supplier network — Genmab (daratumumab originator), BMS + Celgene (lenalidomide + iberdomide + mezigdomide next-gen CELMoDs), Amgen (Kyprolis) — supplying molecules for every HR-SMM combination trial including ASCENT.

Key products: Genmab-originated daratumumab licensed to Janssen 2012 + retained co-royalty. Revlimid (lenalidomide, Celgene → BMS, FDA 2005-12 MDS + 2006-06 R/R MM) — foundational IMiD. Iberdomide + Mezigdomide next-generation CELMoDs Phase 2/3 development. Dexamethasone as generic corticosteroid supplier.

Differentiation: Specifically, next-generation CELMoDs (iberdomide, mezigdomide) offer deeper lymphocyte depletion + potentially favorable tolerability vs lenalidomide. As a result, future ASCENT-like quadruplets may substitute iberdomide for lenalidomide — a franchise transition opportunity for BMS.

Trajectory: Moreover, Genmab retains daratumumab royalty economics across all trials + label expansions including AQUILA + ASCENT. BMS defends IMiD franchise via CELMoD next-generation transition through 2028+.

Key risk: However, Revlimid generic entry 2022+ compresses per-patient economics + potential daratumumab biosimilar entry 2028+ compresses Genmab royalty. Backbone supplier network faces long-term franchise transitions.

---

BD Deals & Strategic Moves

Key business development activity shaping the ASCENT HR-SMM curative-intent competitive landscape:

Deal Timeline

Date	Deal	Parties	Type	Significance
2005-12	Revlimid (lenalidomide) FDA approval MDS + 2006-06 R/R MM	Celgene → BMS	Regulatory — first IMiD	Foundation of IMiD backbone in ASCENT quadruplet
2012-07	Kyprolis (carfilzomib) FDA approval R/R MM	Amgen + Onyx	Regulatory — 2nd-gen PI	Foundation of PI backbone in ASCENT KRd+Dara quadruplet
2012 (pre-approval)	Genmab licenses daratumumab to Janssen	Genmab + Janssen	Global license	Enables Darzalex approval + ASCENT collaboration + AQUILA Phase 3
2015-11	Darzalex (daratumumab) FDA approval R/R MM ≥ 3 prior lines	Janssen (originator Genmab)	Regulatory — first CD38 mAb	Foundation of CD38 mAb backbone across all HR-SMM combinations
2016-01	Kyprolis + Rd 1L MM FDA approval	Amgen	Regulatory — 1L expansion	Established KRd triplet as 1L option; foundation for KRd+Dara quadruplet in ASCENT

Recent Strategic Moves (2019–2026)

Date	Deal	Parties	Type	Significance
2019-01	BMS acquires Celgene for $74B — gains Revlimid + Pomalyst + Abecma programs	BMS + Celgene	M&A	Consolidates IMiD backbone in ASCENT + broader myeloma franchise
2019-06	Darzalex + Rd 1L TI NDMM FDA approval via MAIA Phase 3	Janssen	Regulatory — 1L TI NDMM standard	Established Dara + Rd as 1L standard; validates Dara supply role in HR-SMM ASCENT + AQUILA
2020-05	Darzalex Faspro (daratumumab + hyaluronidase SC) FDA approval	Janssen	Regulatory — SC formulation	Enabled AQUILA Dara SC monotherapy HR-SMM approach + community outpatient administration
2021+	ASCENT enrollment + follow-up phase	IMF + Amgen + Janssen + BMS	Clinical progress	IMF-sponsored Phase 2 KRd+Dara quadruplet in HR-SMM — active, not recruiting; follow-up ongoing
2024-Q1	AQUILA Phase 3 positive readout — Dara SC vs monitoring HR-SMM	Janssen	Practice-changing Phase 3	Established Dara SC monotherapy as HR-SMM early-intervention standard; baseline for ASCENT comparison
2025-2026	ASCENT + DARA RVD PRISM final data readouts	IMF + Dana-Farber	Curative-intent evidence	Cross-institution HR-SMM quadruplet evidence base emerging

Strategic Pattern

Strategic pattern: Overall, the ASCENT theme is patient-advocacy foundation (IMF) leading HR-SMM curative-intent research through pharmaceutical collaboration — Amgen (Kyprolis) + Janssen (Darzalex) + Celgene/BMS (Revlimid). Around ASCENT, Dana-Farber PRISM platform runs parallel quadruplet + BCMA immunotherapy + CAR-T HR-SMM programs; Janssen AQUILA established Dara SC monotherapy standard-of-care 2024; SWOG DETER-SMM Phase 3 Dara + Rd triplet; Regeneron LINKER-SMM2 + Dana-Farber ImmunoPRISM + Pfizer ERASMM test BCMA bispecific monotherapy alternatives; Legend Biotech + J&J CAR-HiRiSMM tests BCMA CAR-T curative-intent. The strategic pattern reveals two things. First, HR-SMM research has fragmented across four treatment philosophies — quadruplet curative-intent (ASCENT, DARA RVD PRISM), CD38 mAb monotherapy (AQUILA), BCMA bispecific/CAR-T single-modality (LINKER-SMM2, ImmunoPRISM, CAR-HiRiSMM), and IMiD-based next-gen (MODIFY iberdomide). Second, guidelines have not yet converged — 2027-2028 will see multi-modality evidence generate treatment-selection frameworks for HR-SMM based on patient fitness, risk stratification, and access considerations.

---

Unmet Needs & White Spaces

Notably, three white spaces meet all three criteria — sparse coverage, clear technical value, and a realistic entry path:

White Space	Current Coverage	Technical Value	Entry Path
Randomized ASCENT quadruplet vs AQUILA Dara SC monotherapy head-to-head (Direct Phase 3 comparison of KRd+Dara curative quadruplet vs Dara SC monotherapy in HR-SMM)	Sparse — ASCENT + AQUILA both single-arm/monotherapy Phase 2/3 with different populations; no direct comparative Phase 3	High — direct comparative evidence essential for HR-SMM guideline positioning; distinguishes tolerability vs efficacy trade-offs	Cooperative-group investigator-sponsored Phase 3; IMF + IMWG protocol beyond ASCENT + AQUILA follow-on
Next-gen CELMoD (iberdomide/mezigdomide) HR-SMM quadruplet extension (Iberdomide-substituted quadruplet replacing lenalidomide in ASCENT-like protocol for potentially better tolerability + efficacy)	Sparse — MODIFY tests Iberdomide + Isatuximab doublet; no next-gen CELMoD-based quadruplet in HR-SMM	High — combines potentially superior IMiD with proven proteasome + CD38 platform for optimized HR-SMM quadruplet	BMS-sponsored + IMF investigator collaboration for next-gen CELMoD quadruplet HR-SMM Phase 2
HR-SMM molecular biomarker-adaptive treatment selection (Genomic + circulating tumor DNA-based selection between ASCENT quadruplet vs AQUILA monotherapy vs BCMA immunotherapy)	Sparse — Current HR-SMM stratification uses 20-2-20 clinical criteria; no molecular biomarker-guided treatment selection framework	High — personalizes HR-SMM treatment intensity to underlying disease biology; optimizes tolerability-efficacy balance per patient	IMWG cooperative-group biomarker-guided Phase 3 platform; align with SPOTLIGHT longitudinal insight trial

---

Risks and Strategic Outlook for 2026 and Beyond

Key Risks

1. Quadruplet tolerability in asymptomatic HR-SMM: However, 24-cycle KRd+Dara exposure in still-asymptomatic HR-SMM patients faces significant risk-benefit scrutiny. If ASCENT quadruplet AE profile exceeds AQUILA Dara SC monotherapy without commensurate MRD or biochemical PFS benefit, community adoption faces resistance.
2. AQUILA Dara SC monotherapy benchmark: Moreover, AQUILA 2024 positive readout established Dara SC monotherapy as HR-SMM early-intervention standard. ASCENT quadruplet must clear meaningful benefit margin over AQUILA + retain acceptable safety to justify quadruplet complexity — a challenging comparative bar.
3. BCMA immunotherapy competition: Notably, LINKER-SMM2 (Regeneron linvoseltamab Phase 3) + ImmunoPRISM (Dana-Farber teclistamab) + CAR-HiRiSMM (Legend + J&J ciltacabtagene) test aggressive BCMA immunotherapy in HR-SMM. If BCMA approaches demonstrate favorable safety + efficacy in HR-SMM, ASCENT quadruplet faces modality-level displacement.
4. Single-arm Phase 2 evidence limitation: Furthermore, ASCENT single-arm design lacks direct randomized comparison. If comparative Phase 3 (against AQUILA or DARA RVD PRISM VRd+Dara) does not follow, guideline adoption of KRd+Dara quadruplet in HR-SMM will remain limited.

Strategic Outlook

For strategic planning, the safest near-term bet around ASCENT is AQUILA Dara SC monotherapy commercial franchise expansion + Genmab royalty economics, where Janssen + Genmab benefit from HR-SMM early-intervention standardization regardless of which curative-intent quadruplet emerges. However, the highest-upside, highest-risk bets are in ASCENT final MRD-negative CR + biochemical PFS readouts where IMF Phase 2 quadruplet must demonstrate meaningful depth-of-response + durability to support Phase 3 confirmatory follow-on, and in ASCENT + DARA RVD PRISM cross-institution quadruplet evidence integration that could establish curative-intent framework in HR-SMM. White-space opportunities exist in randomized quadruplet vs monotherapy Phase 3 head-to-head, next-gen CELMoD-based quadruplet extensions, and molecular biomarker-adaptive treatment selection. The next three years of HR-SMM therapy depend on whether curative-intent quadruplets, CD38 mAb monotherapy, or BCMA immunotherapy emerges as the preferred approach for aggressive smoldering disease intervention.

If you want to generate similar competitive landscape reports for other clinical trials, targets, or drugs, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.